We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pemoline in the Treatment of Stimulant Dependence - 5

This study has been withdrawn prior to enrollment.
(Study was never funded.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000340
First Posted: September 21, 1999
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to assess the efficacy of pemoline in treating cocaine and/or methamphetamine dependent adults with comorbid Adult Attention Deficit Hyperactivity Disorder (ADHD).

Condition Intervention Phase
Cocaine-Related Disorders Drug: Pemoline Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pemoline in the Treatment of Stimulant Dependence

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Retention
  • Depression
  • Incidence of stimulant use
  • Severity of stimulant withdrawal symptoms
  • ADHD symptom severity
  • Degree of drug craving
  • Frequency of IV drug use and sexual risk behaviors

Enrollment: 0
Study Start Date: June 1996
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000340


Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Walter Ling, M.D. Friends Research Institute, Inc.
  More Information

ClinicalTrials.gov Identifier: NCT00000340     History of Changes
Other Study ID Numbers: NIDA-3-0010-5
Y01-3-0010-5
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: January 12, 2017
Last Verified: August 2008

Keywords provided by National Institute on Drug Abuse (NIDA):
cocaine dependence

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Central Nervous System Stimulants
Pemoline
Physiological Effects of Drugs